Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study without human clinical data.
PubMed 23029549 · doi:10.1371/journal.pone.0046549
What was done
Researchers created transgenic mice with cardiomyocyte-specific expression of human aldose reductase (hAR) driven by the alpha-myosin heavy chain promoter. Cardiac function and metabolic gene expression were assessed during aging, in response to experimental myocardial ischemia-reperfusion compared to non-transgenic littermates, and after crossing the transgene onto a PPAR-alpha knockout background characterized by reduced fatty acid oxidation and elevated glucose oxidation.
What was found
The abstract provides directional findings without quantitative metrics. Young hAR transgenic mice showed normal baseline cardiac function and metabolic gene expression. Older hAR transgenic mice developed cardiac dysfunction. Following ischemia-reperfusion, hAR transgenic mice had larger myocardial infarct areas and impaired functional recovery versus non-transgenic controls. On a PPAR-alpha knockout background, hAR-expressing mice exhibited higher cardiac fructose levels, increased myocardial fibrosis, elevated reactive oxygen species (ROS), and increased apoptosis.
Why it matters
These findings suggest that cardiomyocyte aldose reductase activity directly contributes to myocardial injury and heart failure progression, supporting the potential therapeutic investigation of aldose reductase inhibitors in ischemic injury and metabolic cardiac dysfunction.
Limits
The study was performed exclusively in transgenic mouse models, limiting direct translation to human heart disease. The abstract does not report animal sample sizes (n), exact numerical effect sizes, or confidence intervals.
Cited by
- supports Reduced blood flow during a heart attack stimulates local fructose synthesis in the heart via aldose reductase.